{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:17:18Z","timestamp":1789705038431,"version":"4.0.1"},"reference-count":182,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cardiovascular disease remains the leading cause of death and disability worldwide. Coronary artery disease is the most common clinical manifestation. The underlying pathology is largely attributable to atherosclerosis, a chronic inflammatory process that results in the development of atherosclerotic plaques. Coronary artery disease may present as chronic coronary syndrome or acute coronary syndrome, depending on the extent and stability of plaque disruption. The risk of cardiovascular events is modulated by established clinical and metabolic factors, and risk stratification frameworks are provided by international guidelines. Patients undergoing percutaneous coronary intervention are classified as being at very high cardiovascular risk, despite improvements in invasive and non-invasive management. In this population, the residual ischemic risk remains a significant concern, underscoring the need for targeted secondary prevention strategies. The secondary prevention addresses modifiable risk factors, including hypertension, dyslipidemia, diabetes mellitus, overweight and obesity, and tobacco use, along with recommendations for lifestyle modification. Nonetheless, current interventions leave a substantial proportion of patients exposed to future events, indicating a persistent unmet therapeutic need. Emerging evidence highlights the critical roles of lipid metabolism, inflammation, and metabolic dysfunction in the residual risk pathophysiology. This narrative review aims to examine pharmacological strategies targeting metabolic pathways, notably obesity and diabetes, in the context of secondary cardiovascular prevention in patients undergoing percutaneous coronary intervention.<\/jats:p>","DOI":"10.3390\/jcm15031108","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:04:46Z","timestamp":1769778286000},"page":"1108","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimal Medical Therapy Targeting Metabolic Status for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention"],"prefix":"10.3390","volume":"15","author":[{"given":"Imma","family":"Forzano","sequence":"first","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-823X","authenticated-orcid":false,"given":"Viviana","family":"Narciso","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-7464","authenticated-orcid":false,"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"},{"name":"CPC Clinical Research, Department of Medicine, University of Colorado, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-910X","authenticated-orcid":false,"given":"Domenico Simone","family":"Castiello","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3574-3368","authenticated-orcid":false,"given":"Domenico","family":"Florimonte","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Manzi","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Semplice","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato Maria","family":"Vallone","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6096-2768","authenticated-orcid":false,"given":"Stefano","family":"Cristiano","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"D\u2019Alconzo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-517X","authenticated-orcid":false,"given":"Roberta","family":"Paolillo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1687","authenticated-orcid":false,"given":"Giuseppe","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-1235","authenticated-orcid":false,"given":"Arturo","family":"Cesaro","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Cardiology, A.O.R.N. \u201cSant\u2019Anna e San Sebastiano\u201d, 26100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-278X","authenticated-orcid":false,"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Cardiology, A.O.R.N. \u201cSant\u2019Anna e San Sebastiano\u201d, 26100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Cardiology, A.O.R.N. \u201cSant\u2019Anna e San Sebastiano\u201d, 26100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-7127","authenticated-orcid":false,"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4395-6742","authenticated-orcid":false,"given":"Giuseppe","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"ref_1","unstructured":"(2018). GBD 2017 Causes of Death Collaborators. Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980\u20132017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1736\u20131788."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting Cardiovascular Inflammation: Next Steps in Clinical Translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the Management of Chronic Coronary Syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and Diagnostic Criteria of Clinical Obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and Cardiovascular Disease: An ESC Clinical Consensus Statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2017.07.763","article-title":"Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women","volume":"70","author":"Caleyachetty","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Battineni, G., Sagaro, G.G., Chintalapudi, N., Amenta, F., Tomassoni, D., and Tayebati, S.K. (2021). Impact of Obesity-Induced Inflammation on Cardiovascular Diseases (CVD). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094798"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fca-2018-0045","article-title":"Type-2 Diabetes Mellitus and Cardiovascular Disease","volume":"14","author":"Henning","year":"2018","journal-title":"Future Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"i5483","DOI":"10.1136\/bmj.i5483","article-title":"Short Term versus Long Term Dual Antiplatelet Therapy after Implantation of Drug Eluting Stent in Patients with or without Diabetes: Systematic Review and Meta-Analysis of Individual Participant Data from Randomised Trials","volume":"355","author":"Gargiulo","year":"2016","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Forzano, I., Florimonte, D., Narciso, V., Canonico, M.E., Castiello, D.S., Manzi, L., Cristiano, S., Spinelli, A., Vallone, D.M., and D\u2019Alconzo, D. (2025). Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention. J. Clin. Med., 14.","DOI":"10.3390\/jcm14238334"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2459\/JCM.0000000000001723","article-title":"Single vs. Dual Antithrombotic Therapy in Patients with Oral Anticoagulation and Stabilized Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials","volume":"26","author":"Gargiulo","year":"2025","journal-title":"J. Cardiovasc. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Castiello, D.S., Buongiorno, F., Manzi, L., Narciso, V., Forzano, I., Florimonte, D., Sperandeo, L., Canonico, M.E., Avvedimento, M., and Paolillo, R. (2025). Procedural and Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Narrative Review. J. Cardiovasc. Dev. Dis., 12.","DOI":"10.3390\/jcdd12040142"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.clinthera.2025.03.010","article-title":"Long-Term Antithrombotic Therapy in Patients with Chronic Coronary Syndrome: An Updated Review of Current Evidence","volume":"47","author":"Canonico","year":"2025","journal-title":"Clin. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","article-title":"Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions","volume":"17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_17","first-page":"527","article-title":"Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention","volume":"13","author":"Manzi","year":"2024","journal-title":"Interv. Cardiol. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4244\/EIJ-D-17-00468","article-title":"State of the Art: Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention and Coronary Stent Implantation\u2014Past, Present and Future Perspectives","volume":"13","author":"Gargiulo","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy vs. Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","article-title":"A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?","volume":"134","author":"Gargiulo","year":"2016","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.05.085","article-title":"Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: Do Bleeding and Stent Thrombosis Weigh Similar on Mortality?","volume":"66","author":"Capodanno","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e082561","DOI":"10.1136\/bmj-2024-082561","article-title":"P2Y12 Inhibitor or Aspirin after Percutaneous Coronary Intervention: Individual Patient Data Meta-Analysis of Randomised Clinical Trials","volume":"389","author":"Giacoppo","year":"2025","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jcin.2016.12.003","article-title":"Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients with and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry","volume":"10","author":"Faggioni","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.jcin.2025.06.031","article-title":"Short DAPT After PCI for ACS: Which Monotherapy Is Better Between Aspirin or a P2Y12 Inhibitor?","volume":"18","author":"Gargiulo","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.4244\/EIJ-D-24-00992","article-title":"Antithrombotic Therapy in Complex Percutaneous Coronary Intervention","volume":"21","author":"Castiello","year":"2025","journal-title":"EuroIntervention"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus Aspirin for Secondary Prevention of Coronary Artery Disease: A Systematic Review and Individual Patient Data Meta-Analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2018.08.055","article-title":"Contemporary Management of Patients Referring to Cardiologists One to Three Years from a Myocardial Infarction: The EYESHOT Post-MI Study","volume":"273","author":"Piscione","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of Secondary Prevention Drugs for Cardiovascular Disease in the Community in High-Income, Middle-Income, and Low-Income Countries (the PURE Study): A Prospective Epidemiological Survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/2047487320912491","article-title":"Profile and Treatment of Chronic Coronary Syndromes in European Society of Cardiology Member Countries: The ESC EORP CICD-LT Registry","volume":"28","author":"Komajda","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e70003","DOI":"10.1002\/cph4.70003","article-title":"Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies","volume":"15","author":"Singh","year":"2025","journal-title":"Compr. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee 2 (2025). Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care, 48, S27\u2013S49.","DOI":"10.2337\/dc25-S002"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/CIRCULATIONAHA.112.127514","article-title":"Protein Kinase-C Beta Contributes to Impaired Endothelial Insulin Signaling in Humans with Diabetes Mellitus","volume":"127","author":"Tabit","year":"2013","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Poznyak, A., Grechko, A.V., Poggio, P., Myasoedova, V.A., Alfieri, V., and Orekhov, A.N. (2020). The Diabetes Mellitus\u2013Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051835"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107834","DOI":"10.1016\/j.jdiacomp.2020.107834","article-title":"Homocysteine and Diabetes: Role in Macrovascular and Microvascular Complications","volume":"35","author":"Solak","year":"2021","journal-title":"J. Diabetes Complicat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ahj.2021.10.181","article-title":"Incidence Rates and Predictors of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes: Results from the Longitudinal Global Discover Study","volume":"243","author":"Arnold","year":"2022","journal-title":"Am. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00125-005-1832-1","article-title":"Atherosclerosis in Childhood and Adolescent Type 1 Diabetes: Early Disease, Early Treatment?","volume":"48","author":"Larsen","year":"2005","journal-title":"Diabetologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.2337\/dc06-1161","article-title":"Type 1 Diabetes and Coronary Artery Disease","volume":"29","author":"Orchard","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.biocel.2005.09.015","article-title":"Soluble Interleukin-2 Receptor as a Marker for Progression of Coronary Artery Calcification in Type 1 Diabetes","volume":"38","author":"Wadwa","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2174\/0929867326666190119154152","article-title":"Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice","volume":"27","author":"Tentolouris","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40292-020-00400-2","article-title":"New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics","volume":"27","author":"Ambrosini","year":"2020","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.2174\/1381612826666200417145605","article-title":"Antithrombotic Treatment in Diabetes Mellitus: A Review of the Literature about Antiplatelet and Anticoagulation Strategies Used for Diabetic Patients in Primary and Secondary Prevention","volume":"26","author":"Siasos","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00076","DOI":"10.1002\/edm2.76","article-title":"The Prevalence of Cardiovascular Disease and Antidiabetes Treatment Characteristics among a Large Type 2 Diabetes Population in the United States","volume":"2","author":"Weng","year":"2019","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40256-020-00424-y","article-title":"The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach","volume":"21","author":"Fras","year":"2021","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"262","DOI":"10.21037\/atm.2020.03.15","article-title":"Mitochondria and Diabetes","volume":"8","author":"Siasos","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee 10 (2025). Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care, 48, S207\u2013S238.","DOI":"10.2337\/dc25-S010"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(99)08415-9","article-title":"Stress Hyperglycaemia and Increased Risk of Death after Myocardial Infarction in Patients with and without Diabetes: A Systematic Overview","volume":"355","author":"Capes","year":"2000","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12933-022-01460-5","article-title":"Diabetes and Restenosis","volume":"21","author":"Wilson","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jacc.2024.04.012","article-title":"Glycemic Control and Coronary Stent Failure in Patients with Type 2 Diabetes Mellitus","volume":"84","author":"Lagerqvist","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cesaro, A., De Michele, G., Fimiani, F., Acerbo, V., Scherillo, G., Signore, G., Rotolo, F.P., Scialla, F., Raucci, G., and Panico, D. (2023). Visceral Adipose Tissue and Residual Cardiovascular Risk: A Pathological Link and New Therapeutic Options. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1187735"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European Society of Cardiology: Cardiovascular Disease Statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Global BMI Mortality Collaboration, Di Angelantonio, E., Bhupathiraju, S., Wormser, D., Gao, P., Kaptoge, S., Berrington de Gonzalez, A., Cairns, B., Huxley, R., and Jackson, C. (2016). Body-Mass Index and All-Cause Mortality: Individual-Participant-Data Meta-Analysis of 239 Prospective Studies in Four Continents. Lancet, 388, 776\u2013786.","DOI":"10.1016\/S0140-6736(16)30175-1"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"GBD 2015 Obesity Collaborators, Afshin, A., Forouzanfar, M.H., Reitsma, M.B., Sur, P., Estep, K., Lee, A., Marczak, L., Mokdad, A.H., and Moradi-Lakeh, M. (2017). Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N. Engl. J. Med., 377, 13\u201327.","DOI":"10.1056\/NEJMoa1614362"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/cvr\/cvab080","article-title":"New Aspects of Endocrine Control of Atrial Fibrillation and Possibilities for Clinical Translation","volume":"117","author":"Aguilar","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/eurheartj\/ehx181","article-title":"Position Paper of the European Society of Cardiology-Working Group of Coronary Pathophysiology and Microcirculation: Obesity and Heart Disease","volume":"38","author":"Badimon","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"i2156","DOI":"10.1136\/bmj.i2156","article-title":"BMI and All Cause Mortality: Systematic Review and Non-Linear Dose-Response Meta-Analysis of 230 Cohort Studies with 3.74 Million Deaths among 30.3 Million Participants","volume":"353","author":"Aune","year":"2016","journal-title":"BMJ"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2013.05.058","article-title":"In-Hospital Outcomes of Percutaneous Coronary Interventions in Extremely Obese and Normal-Weight Patients: Findings from the NCDR (National Cardiovascular Data Registry)","volume":"62","author":"Payvar","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jacc.2013.06.004","article-title":"The Burgeoning Epidemic of Morbid Obesity in Patients Undergoing Percutaneous Coronary Intervention: Insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium","volume":"62","author":"Buschur","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/cvr\/cvx106","article-title":"The Molecular Mechanisms of Obesity Paradox","volume":"113","author":"Antonopoulos","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12933-025-02778-6","article-title":"Refining the Link between Obesity and Heart Failure: Insights from GLP-1 Receptor Agonist Trials and Studies Adopting Direct Adiposity Measures","volume":"24","author":"Pugliese","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1093\/eurheartj\/ehaf409","article-title":"Redefining Obesity: Beyond Body Mass Index","volume":"46","author":"Butler","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1093\/eurheartj\/ehad484","article-title":"Perivascular Adipose Tissue as a Source of Therapeutic Targets and Clinical Biomarkers","volume":"44","author":"Antoniades","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kumar, R.K., Jin, Y., Watts, S.W., and Rockwell, C.E. (2020). Na\u00efve, Regulatory, Activated, and Memory Immune Cells Co-Exist in PVATs That Are Comparable in Density to Non-PVAT Fats in Health. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.00058"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/VHRM.S33760","article-title":"The Influence of Perivascular Adipose Tissue on Vascular Homeostasis","volume":"9","author":"Szasz","year":"2013","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.thromres.2015.07.015","article-title":"Obesity and Antiplatelets-Does One Size Fit All?","volume":"136","author":"Beavers","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10557-022-07322-2","article-title":"Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response","volume":"37","author":"Scudiero","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Guh, D.P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C.L., and Anis, A.H. (2009). The Incidence of Co-Morbidities Related to Obesity and Overweight: A Systematic Review and Meta-Analysis. BMC Public Health, 9.","DOI":"10.1186\/1471-2458-9-88"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1210\/clinem\/dgaa620","article-title":"Association Between Body Size Phenotypes and Subclinical Atherosclerosis","volume":"105","author":"Rossello","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ferhatbegovi\u0107, L., Mr\u0161i\u0107, D., and Maci\u0107-D\u017eankovi\u0107, A. (2023). The Benefits of GLP1 Receptors in Cardiovascular Diseases. Front. Clin. Diabetes Healthc., 4.","DOI":"10.3389\/fcdhc.2023.1293926"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging Glucagon-like Peptide 1 Receptor Agonists for the Treatment of Obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2213-8587(25)00166-4","article-title":"Incretins and the Cardiovascular System: Bridging Digestion with Metabolism","volume":"13","author":"Avogaro","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Basile, C., Merolla, A., Mancusi, C., De Luca, C., Fucile, I., Canonico, M.E., Giugliano, G., Orso, F., Morisco, C., and Esposito, G. (Eur. J. Prev. Cardiol., 2025). Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis, Eur. J. Prev. Cardiol., Online ahead of print.","DOI":"10.1093\/eurjpc\/zwaf560"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ahj.2015.02.002","article-title":"Rationale, Design, and Baseline Characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a Long-Term Cardiovascular End Point Trial of Lixisenatide versus Placebo","volume":"169","author":"Aguilar","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison with Placebo in Patients with Type 2 Diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ehjcvp\/pvad080","article-title":"FLOW Trial Stopped Early Due to Evidence of Renal Protection with Semaglutide","volume":"10","author":"Gragnano","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE): A Phase 3b, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral Semaglutide Versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Cesaro, A., Pastori, D., Acerbo, V., Biccir\u00e8, F.G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G.Y.H., and Calabr\u00f2, P. (Eur. J. Prev. Cardiol., 2025). Reduction of New Onset of Atrial Fibrillation in Patients Treated with Semaglutide: An Updated Systematic Review and Meta Regression Analysis of Randomized Controlled Trials, Eur. J. Prev. Cardiol., Online ahead of print.","DOI":"10.1093\/eurjpc\/zwaf257"},{"key":"ref_91","first-page":"100063","article-title":"Role of Glucagon-like Peptide-1 Agonist in Patients Undergoing Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Meta-Analysis","volume":"11","author":"Ogbu","year":"2021","journal-title":"Am. Heart J. Plus"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S.S., Mone, P., and Santulli, G. (2022). Tirzepatide: A Systematic Update. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314631"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1093\/eurheartj\/ehab636","article-title":"Is Tirzepatide in the Surpass Lane over GLP-1 Receptor Agonists for the Treatment of Diabetes?","volume":"42","author":"Paneni","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0140-6736(21)01390-8","article-title":"Tirzepatide and the New Era of Twincretins for Diabetes","volume":"398","author":"Tan","year":"2021","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"SURPASS-2 Investigators Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e026297","DOI":"10.1161\/JAHA.122.026297","article-title":"Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control","volume":"11","author":"Chiu","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-Label, Parallel-Group, Phase 3 Trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2213-8587(22)00074-2","article-title":"Tirzepatide Adds Hepatoprotection to Its Armoury","volume":"10","author":"Targher","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of Tirzepatide versus Insulin Degludec on Liver Fat Content and Abdominal Adipose Tissue in People with Type 2 Diabetes (SURPASS-3 MRI): A Substudy of the Randomised, Open-Label, Parallel-Group, Phase 3 SURPASS-3 Trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): A Randomised, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial","volume":"398","author":"Kahn","year":"2021","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of Tirzepatide versus Insulin Glargine on Kidney Outcomes in Type 2 Diabetes in the SURPASS-4 Trial: Post-Hoc Analysis of an Open-Label, Randomised, Phase 3 Trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jama.2021.25016","article-title":"Tirzepatide for Patients with Type 2 Diabetes","volume":"327","author":"Chipkin","year":"2022","journal-title":"JAMA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and Safety of Tirzepatide Monotherapy Compared with Dulaglutide in Japanese Patients with Type 2 Diabetes (SURPASS J-Mono): A Double-Blind, Multicentre, Randomised, Phase 3 Trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/dom.14882","article-title":"Change in Pharmacodynamic Variables Following Once-Weekly Tirzepatide Treatment versus Dulaglutide in Japanese Patients with Type 2 Diabetes (SURPASS J-Mono Substudy)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","article-title":"Safety and Efficacy of Tirzepatide as an Add-on to Single Oral Antihyperglycaemic Medication in Patients with Type 2 Diabetes in Japan (SURPASS J-Combo): A Multicentre, Randomised, Open-Label, Parallel-Group, Phase 3 Trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am. Heart J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_111","first-page":"100335","article-title":"SGLT2 Inhibitors: Beyond Glycemic Control","volume":"35","author":"Hasan","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of Human Sodium Glucose Transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes","volume":"384","author":"Kalyani","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 Inhibitors on Cardiovascular, Renal and Safety Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/ehjcvp\/pvab039","article-title":"SGLT2 Inhibitors in Cardiovascular Medicine","volume":"7","author":"Varzideh","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101061","DOI":"10.1016\/j.ajpc.2025.101061","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Atherosclerosis","volume":"23","author":"Ceasovschih","year":"2025","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.012","article-title":"The Design and Rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial","volume":"200","author":"Wiviott","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dom.13217","article-title":"DECLARE-TIMI 58: Participants\u2019 Baseline Characteristics","volume":"20","author":"Raz","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, Design, and Baseline Characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a Randomized Placebo-Controlled Trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, Design and Baseline Characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A Randomized, Placebo-Controlled Trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/dom.12924","article-title":"Optimizing the Analysis Strategy for the CANVAS Program: A Prespecified Plan for the Integrated Analyses of the CANVAS and CANVAS-R Trials","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes: Results from the CANVAS Program Randomised Clinical Trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2020.12.008","article-title":"Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants with Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results from the CREDENCE Trial","volume":"233","author":"Sarraju","year":"2021","journal-title":"Am. Heart J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","article-title":"Design and Baseline Characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)","volume":"206","author":"Cannon","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of Sotagliflozin on Major Adverse Cardiovascular Events: A Prespecified Secondary Analysis of the SCORED Randomised Trial","volume":"13","author":"Aggarwal","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in Acute Myocardial Infarction: The EMMY Trial","volume":"43","author":"Kolesnik","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after Acute Myocardial Infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10741-020-09954-8","article-title":"Comparative Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) for Cardiovascular Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","volume":"26","author":"Atar","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic Insights of Empagliflozin in Nondiabetic Patients with HFrEF: From the EMPA-TROPISM Study","volume":"9","author":"Mancini","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A Trial to Evaluate the Effect of the Sodium-Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jchf.2020.04.008","article-title":"Effect of Dapagliflozin in Patients with HFrEF Treated with Sacubitril\/Valsartan: The DAPA-HF Trial","volume":"8","author":"Solomon","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/obr.12889","article-title":"Management of Overweight and Obesity in Primary Care-A Systematic Overview of International Evidence-Based Guidelines","volume":"20","author":"Semlitsch","year":"2019","journal-title":"Obes. Rev."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"535918","DOI":"10.1155\/2010\/535918","article-title":"Inflammation, a Link between Obesity and Cardiovascular Disease","volume":"2010","author":"Wang","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CRD.0000000000000513","article-title":"Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity","volume":"32","author":"Mullally","year":"2024","journal-title":"Cardiol. Rev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-Term Drug Treatment for Obesity: A Systematic and Clinical Review","volume":"311","author":"Yanovski","year":"2014","journal-title":"JAMA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","article-title":"Naltrexone\/Bupropion for Obesity: An Investigational Combination Pharmacotherapy for Weight Loss","volume":"84","author":"Billes","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"NN8022-1923 Investigators Weight Maintenance and Additional Weight Loss with Liraglutide after Low-Calorie-Diet-Induced Weight Loss: The SCALE Maintenance Randomized Study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int. J. Obes."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"NN8022-1922 Study Group Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: A Randomised, Double-Blind Trial","volume":"389","author":"Astrup","year":"2017","journal-title":"Lancet"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 Mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 Mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/dom.15386","article-title":"Efficacy and Safety of Semaglutide 2.4\u2009Mg for Weight Loss in Overweight or Obese Adults without Diabetes: An Updated Systematic Review and Meta-Analysis Including the 2-Year STEP 5 Trial","volume":"26","author":"Qin","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"STEP 8 Investigators Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"OASIS 4 Study Group Oral Semaglutide at a Dose of 25 Mg in Adults with Overweight or Obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/dom.70209","article-title":"Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis: Rationale and Design of the TRIUMPH Registrational Clinical Trials","volume":"28","author":"Giblin","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/dom.15184","article-title":"Orforglipron (LY3502970), a Novel, Oral Non-Peptide Glucagon-like Peptide-1 Receptor Agonist: A Phase 1a, Blinded, Placebo-Controlled, Randomized, Single- and Multiple-Ascending-Dose Study in Healthy Participants","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"101740","DOI":"10.1016\/j.jacadv.2025.101740","article-title":"An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists","volume":"4","author":"Dani","year":"2025","journal-title":"JACC Adv."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, Preserved Ejection Fraction, and Obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10741-025-10524-z","article-title":"Heart Failure with Preserved Ejection Fraction Therapeutics: In Search of the Pillars","volume":"30","author":"Rafei","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure: A Report of the American College of Cardiology","volume":"86","author":"Kittleson","year":"2025","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:34:40Z","timestamp":1770788080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":182,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15031108"],"URL":"https:\/\/doi.org\/10.3390\/jcm15031108","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}